General Information of Drug (ID: DMIVGYK)

Drug Name
SL-801 Drug Info
Synonyms CMASLSTVVOYJQY-UHFFFAOYSA-N; 1076235-04-5; SCHEMBL1592515; S-03747; 1H-Pyrrole-2,5-dione, 1-[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-3-[(3,3-dimethylbutoxy)methyl]-4-methyl-
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
25103750
CAS Number
CAS 1076235-04-5
TTD Drug ID
DMIVGYK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug(s) Targeting Exportin-1 (XPO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selinexor DMBD4K3 Multiple myeloma 2A83 Phase 3 [2]
Selinexor oral DMDLOBZ Recurrent glioblastoma 2A00.00 Phase 2 [3]
Eltanexor oral DM7CLEZ Colorectal cancer 2B91.Z Phase 1/2 [1]
KOS-1815 DMCGFY6 Solid tumour/cancer 2A00-2F9Z Preclinical [2]
S109 DM2JYQA Solid tumour/cancer 2A00-2F9Z Investigative [4]
Octahydrocurcumin DMUFDR6 Solid tumour/cancer 2A00-2F9Z Investigative [5]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Exportin-1 (XPO1) TTCJUR4 XPO1_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-B signaling pathway. Cancer Cell Int. 2020 Mar 30;20:97.
5 Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021 Jan;20(1):21-38.